Revolution Medicines Stock Forecast

Stock Price Forecast

According to 21 analysts polled by S&P Global, Revolution Medicines stock has a consensus rating of "Strong Buy" and an average price target of $187.29. The average 1-year stock price forecast is 2.86% higher than the current stock price, while the lowest is $151 (-17.07%) and the highest is $263 (+44.44%).

Price Target: $187.29 (+2.86%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$151	$187.29	$183	$263
Change	-17.07%	+2.86%	+0.51%	+44.44%

Analyst Ratings

The average analyst rating for Revolution Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	16	17	17	17	17	16
Buy	4	4	4	4	4	4
Hold	0	0	0	0	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	20	21	21	21	22	21

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Gregory Renza Truist Financial	Truist Financial	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Jun 25, 2026
Michael Schmidt Guggenheim	Guggenheim	Buy Maintains $205	Buy	Maintains	$205	+12.59%	Jun 25, 2026
Brian Cheng J.P. Morgan	J.P. Morgan	Buy Reiterates $175 → $200	Buy	Reiterates	$175 → $200	+9.84%	Jun 25, 2026
Alec Stranahan Bank of America Securities	Bank of America Securities	Buy Reiterates $185 → $212	Buy	Reiterates	$185 → $212	+16.43%	Jun 25, 2026
Charles Zhu LifeSci Capital	LifeSci Capital	Buy Maintains $263	Buy	Maintains	$263	+44.44%	Jun 23, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

102.95M

Revenue Next Year

830.24M

from 102.95M

706.44%

from 102.95M

EPS This Year

-8.01

from -5.95

EPS Next Year

-5.70

from -8.01

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	29.39M	35.38M	11.58M	-	-	102.95M
Gross Profit	-157.56M	-217.69M	-407.86M	-592.23M	-987.33M	97.08M
Gross Margin	-536.09%	-615.30%	-3,522.14%	-	-	94.30%
Operating Income	-188.01M	-258.28M	-475.99M	-689.52M	-1.18B	-1.70B
Net Income	-187.09M	-248.71M	-436.37M	-600.09M	-1.13B	-1.65B
EPS	-	-	-	-	-5.95	-8.01
Free Cash Flow	-84.69M	-132.84M	-163.95M	-347.69M	-523.28M	-1.39B
No. Analysts	-	-	-	-	-	20

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	295.1M
Avg	103.0M
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	2,245.4%
Avg	706.4%
Low	39.3%

EPS Forecast

EPS	2026	2027	2028
High	-7.20
Avg	-8.01
Low	-8.81

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-